Savolitinib Clinical Trials (2026): 36 Studies for Non-small Cell Lung Cancer & Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
36 Savolitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 27 indications (including Non-small Cell Lung Cancer & Carcinoma) and 10,478 total planned enrollment. 6 Phase 3 Savolitinib trials and 18 Phase 2 are listed. 6 Savolitinib clinical trials are actively recruiting. Most recent activity: NCT06692491 (Dec 2029).
Savolitinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| P1 | 1 | 9 | 1 | 11 | ||||
| P1/P2 | 1 | 1 | ||||||
| P2 | 4 | 6 | 4 | 1 | 1 | 2 | 18 | |
| P3 | 4 | 2 | 6 |
Recruiting Savolitinib clinical trials (6)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06692491 | SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | Rare Tumour | 200 | Jan 2025 |
| NCT06563999 | NUMERNeoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | P2 | Lung Cancer Stage III | 120 | Nov 2024 |
| NCT04322890 | PIKACHUTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | P2 | Non Small Cell Lung Cancer | 6,000 | Apr 2020 |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | P1/P2 | Non-small Cell Lung Cancer | 29 | Jul 2023 |
| NCT05620628 | MEDI4736Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | P2 | Stomach Cancer, Adenocarcinoma | 25 | Jan 2023 |
| NCT07322783 | Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification | P2 | EGFR Positive Non-small Cell Lung Cancer | 60 | Jan 2025 |
Savolitinib clinical trials by indication
Non-small Cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05009836 | SANOVO | P3 | active not recruiting | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC |
| NCT05777278 | — | P1/P2 | recruiting | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression |
| NCT05015608 | SACHI | P3 | completed | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification |
| NCT03833440 | PIONeeR | P2 | unknown | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance |
Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03778229 | SAVANNAH | P2 | active not recruiting | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib |
| NCT03091192 | — | P3 | active not recruiting | Savolitinib vs. Sunitinib in MET-driven PRCC. |
| NCT05261399 | SAFFRON | P3 | active not recruiting | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment |
Healthy Male Subjects (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05888207 | — | P1 | completed | A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects |
| NCT05768360 | — | P1 | completed | A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects |
Non-small Cell Lung Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04923945 | NSCLC | P3 | completed | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients |
| NCT02117167 | SAFIR02_Lung | P2 | completed | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients |
Non-Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04606771 | CoC | P2 | active not recruiting | A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC |
| NCT03944772 | ORCHARD | P2 | active not recruiting | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) |
Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04187456 | — | P1 | completed | A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body |
| NCT04118842 | — | P1 | completed | A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin |
Rare Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692491 | SPRING | P2 | not yet recruiting | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
EGFR Positive Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07322783 | — | P2 | recruiting | Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification |
Lung Cancer Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06563999 | NUMER | P2 | recruiting | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06348355 | — | P1 | completed | A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers |
Stomach Cancer, Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05620628 | MEDI4736 | P2 | recruiting | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) |
Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05374603 | SOUND | P2 | active not recruiting | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC |
Carcinoma, Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05163249 | FLOWERS | P2 | active not recruiting | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC |
Papillary Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05043090 | SAMETA | P3 | active not recruiting | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC |
Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04923932 | — | P2 | completed | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients |
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04675021 | — | P1 | completed | Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04322890 | PIKACHU | P2 | recruiting | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation |
Solid Tumours (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04179071 | — | P1 | completed | A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine |
Solid Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04121910 | — | P1 | completed | A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole |
Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03592641 | — | P2 | terminated | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer |
Bioequivalence (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03860948 | — | P1 | completed | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers |
Recurrent Diffuse Intrinsic Pontine Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03598244 | — | P1 | active not recruiting | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors |
Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03385655 | — | P2 | active not recruiting | Prostate Cancer Biomarker Enrichment and Treatment Selection |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02630420 | — | P1 | withdrawn | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer |
Lung Sarcomatoid Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02897479 | — | P2 | unknown | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer |
Locally Advanced Papillary Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02761057 | — | P2 | completed | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed |
Renal Clear Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02819596 | CALYPSO | P2 | completed | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma |
Savolitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SANOVO | NCT05009836 | P3 | active not recruiting | Non-small Cell Lung Cancer | 412 | — |
| SAMETA | NCT05043090 | P3 | active not recruiting | Papillary Renal Cell Carcinoma | 148 | — |
| SAFFRON | NCT05261399 | P3 | active not recruiting | Carcinoma | 345 | — |
| SACHI | NCT05015608 | P3 | completed | Non-small Cell Lung Cancer | 216 | PMID 41544643 |
| NSCLC | NCT04923945 | P3 | completed | Non-small Cell Lung Cancer Metastatic | 203 | PMID 41938023 |
| SPRING | NCT06692491 | P2 | not yet recruiting | Rare Tumour | 200 | — |
| NUMER | NCT06563999 | P2 | recruiting | Lung Cancer Stage III | 120 | — |
| PIKACHU | NCT04322890 | P2 | recruiting | Non Small Cell Lung Cancer | 6,000 | — |
| MEDI4736 | NCT05620628 | P2 | recruiting | Stomach Cancer, Adenocarcinoma | 25 | — |
| SOUND | NCT05374603 | P2 | active not recruiting | Lung Cancer | 47 | — |
| SAVANNAH | NCT03778229 | P2 | active not recruiting | Carcinoma | 367 | PMID 41308232 |
| FLOWERS | NCT05163249 | P2 | active not recruiting | Carcinoma, Non-Small-Cell Lung | 44 | PMID 41530133 |
| CoC | NCT04606771 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 30 | — |
| ORCHARD | NCT03944772 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 247 | PMID 34389237 |
| PIONeeR | NCT03833440 | P2 | unknown | Non-small Cell Lung Cancer | 114 | — |
| CALYPSO | NCT02819596 | P2 | completed | Renal Clear Cell Carcinoma | 69 | PMID 36809050 |
| SAFIR02_Lung | NCT02117167 | P2 | completed | Non-small Cell Lung Cancer Metastatic | 999 | PMID 26410619 |
Terminated and withdrawn Savolitinib trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03592641terminatedSavolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
- NCT02630420withdrawnCetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
All Savolitinib trials (36)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06692491 | SPRING | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | not yet recruiting | 200 | Peking University Shenzhen Hospital | Jan 2025 |
| NCT06563999 | NUMER | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | P2 | recruiting | 120 | Sun Yat-sen University | Nov 2024 |
| NCT05009836 | SANOVO | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | P3 | active not recruiting | 412 | Hutchison Medipharma Limited | Sep 2021 |
| NCT04322890 | PIKACHU | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | P2 | recruiting | 6,000 | Hunan Province Tumor Hospital | Apr 2020 |
| NCT05777278 | Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression | P1/P2 | recruiting | 29 | The First Affiliated Hospital of Guangzhou Medical University | Jul 2023 | |
| NCT05620628 | MEDI4736 | Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) | P2 | recruiting | 25 | Jeeyun Lee | Jan 2023 |
| NCT05043090 | SAMETA | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC | P3 | active not recruiting | 148 | AstraZeneca | Oct 2021 |
| NCT05374603 | SOUND | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | P2 | active not recruiting | 47 | AstraZeneca | Nov 2022 |
| NCT07322783 | Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification | P2 | recruiting | 60 | Qingdao Central Hospital | Jan 2025 | |
| NCT03778229 | SAVANNAH | Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | P2 | active not recruiting | 367 | AstraZeneca | Jan 2019 |
| NCT03091192 | Savolitinib vs. Sunitinib in MET-driven PRCC. | P3 | active not recruiting | 60 | AstraZeneca | Jul 2017 | |
| NCT05261399 | SAFFRON | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | P3 | active not recruiting | 345 | AstraZeneca | Aug 2022 |
| NCT05163249 | FLOWERS | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | P2 | active not recruiting | 44 | Guangdong Association of Clinical Trials | May 2022 |
| NCT04923932 | Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients | P2 | completed | 110 | Hutchison Medipharma Limited | Jul 2021 | |
| NCT03598244 | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | P1 | active not recruiting | 41 | National Cancer Institute (NCI) | Nov 2018 | |
| NCT04606771 | CoC | A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC | P2 | active not recruiting | 30 | AstraZeneca | Sep 2020 |
| NCT03385655 | Prostate Cancer Biomarker Enrichment and Treatment Selection | P2 | active not recruiting | 200 | Canadian Cancer Trials Group | Aug 2018 | |
| NCT05015608 | SACHI | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | P3 | completed | 216 | Hutchison Medipharma Limited | Nov 2021 |
| NCT03944772 | ORCHARD | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | P2 | active not recruiting | 247 | AstraZeneca | Jun 2019 |
| NCT03833440 | PIONeeR | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance | P2 | unknown | 114 | Assistance Publique Hopitaux De Marseille | Oct 2019 |
| NCT04923945 | NSCLC | Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | P3 | completed | 203 | Hutchison Medipharma Limited | Aug 2021 |
| NCT02819596 | CALYPSO | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma | P2 | completed | 69 | Queen Mary University of London | May 2016 |
| NCT06348355 | A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers | P1 | completed | 7 | AstraZeneca | Apr 2024 | |
| NCT02117167 | SAFIR02_Lung | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | P2 | completed | 999 | UNICANCER | Apr 2014 |
| NCT02761057 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | P2 | completed | 152 | National Cancer Institute (NCI) | Jul 2016 | |
| NCT05888207 | A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects | P1 | completed | 16 | AstraZeneca | Jun 2023 | |
| NCT05768360 | A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects | P1 | completed | 6 | AstraZeneca | Apr 2023 | |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | P2 | terminated | 5 | National Cancer Institute (NCI) | Jul 2019 | |
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | P2 | unknown | 76 | Hutchison Medipharma Limited | Dec 2016 | |
| NCT04675021 | Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects | P1 | completed | 8 | AstraZeneca | Nov 2020 | |
| NCT04179071 | A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine | P1 | completed | 16 | AstraZeneca | Dec 2019 | |
| NCT04187456 | A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body | P1 | completed | 14 | AstraZeneca | Dec 2019 | |
| NCT04118842 | A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin | P1 | completed | 40 | AstraZeneca | Oct 2019 | |
| NCT04121910 | A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole | P1 | completed | 16 | AstraZeneca | Nov 2019 | |
| NCT03860948 | A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers | P1 | completed | 36 | Hutchison Medipharma Limited | Apr 2019 | |
| NCT02630420 | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | P1 | withdrawn | 0 | Yale University | Jan 2017 |
Savolitinib clinical trials: frequently asked questions
- How many Savolitinib clinical trials are there?
- 36 Savolitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 15 are marked completed.
- Are Savolitinib clinical trials recruiting in 2026?
- Yes — 5 Savolitinib trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Savolitinib being studied for?
- Savolitinib is being studied for Non-small Cell Lung Cancer, Carcinoma, Non-small Cell Lung Cancer Metastatic, Healthy Male Subjects, Solid Tumors and 71 more. The trials are grouped by indication on this page.
- What phase is Savolitinib in?
- Savolitinib clinical trials span 6 Phase 3, 18 Phase 2, 11 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Savolitinib clinical trials?
- The lead sponsor across the most Savolitinib trials is AstraZeneca, with 14 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Savolitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: